title: Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
abstract: To determine if the 10-year rule should apply to men with high-grade, clincially localized prostate cancer, we characterized the survival benefits of aggressive (surgery, radiation, brachytherapy) over nonaggressive treatment (watchful waiting, active surveillance) among older men with differing comorbidity at diagnosis.
  
  
  
  We sampled 44,521 men older than 65 with cT1-2, poorly differentiated prostate cancer diagnosed in 1991-2007 from the Surveillance, Epidemiology, and End Results-Medicare database. We used propensity-adjusted, competing-risks regression to calculate 5- and 10-year cancer mortality among those treated aggressively and nonaggressively across comorbidity subgroups. We determined 5- and 10-year absolute risk reduction in cancer mortality and numbers needed to treat to prevent one cancer death at 10 years.
  
  
  
  In propensity-adjusted, competing-risks regression analysis, aggressive treatment was associated with significantly lower risk of cancer mortality for those with Charlson scores of 0 (sub-hazard ratio (SHR) 0.43, 95% confidence interval [CI] 0.39-0.47), 1 (SHR 0.48, 95% CI 0.40-0.58), and 2 (SHR 0.46, 95% CI 0.34-0.62) but not 3+ (SHR 0.68, 95% CI 0.44-1.07). Absolute reductions in cancer mortality between those treated aggressively and nonaggressively were 7%, 5.5%, 6.9%, and 2.5% at 5 years, and 11.3%, 7.9%, 8.6%, and 2.8% at 10 years for men with Charlson scores of 0, 1, 2, and 3+ , respectively; numbers needed to treat to prevent 1 cancer death at 10 years were 9, 13, 12, and 36 men.
  
  
  
  The 10-year rule may not apply to men with high-grade, clinically localized disease. Older men with Charlson scores ≤2 should consider aggressive treatment of such disease due to its substantial short-term cancer survival benefits.
authors.affiliation: Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Timothy.Daskivich@csmc.edu.
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Daskivich
authors.affiliation: RAND Corporation, Santa Monica, CA.
authors.forename: Julie
authors.initials: J
authors.lastname: Lai
authors.affiliation: RAND Corporation, Santa Monica, CA.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Dick
authors.affiliation: RAND Corporation, Santa Monica, CA.
authors.forename: Claude M
authors.initials: CM
authors.lastname: Setodji
authors.affiliation: RAND Corporation, Santa Monica, CA.
authors.forename: Janet M
authors.initials: JM
authors.lastname: Hanley
authors.affiliation: Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, CA.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Litwin
authors.affiliation: RAND Corporation, Santa Monica, CA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, CA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Saigal
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D006801:Humans; D008017:Life Expectancy; D008297:Male; D060787:Neoplasm Grading; D011471:Prostatic Neoplasms / Q000150:complications / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors